Adler M. Noninvasive assessment of liver fibrosis with aspartate transaminase to platelet ratio index (APRI). In chronic liver diseases, the management of patients must include a determination of the stage of fibrosis (to select specific therapies), a prognosis, the prevention of complications, and the surveillance of the disease. Over the past several years, significant progress has been made ...

OBJECTIVES Although liver biopsy is the gold standard for determining the degree of liver fibrosis, issues regarding its invasiveness and the small amount of liver tissue evaluated can limit its applicability and interpretation in clinical practice. Non-invasive evaluation methods for liver fibrosis can address some of these limitations. The aim of this study was to evaluate the accuracy of tra...

Guzelbulut et al. (1) demonstrated that the aspartate aminotransferase (AST)-platelet ratio index (APRI) may be a useful noninvasive marker in the exclusion of both significant fibrosis and cirrhosis because of the high negative predictive values (NPVs) in chronic hepatitis B (CHB). However, the NPVs for significant fibrosis and cirrhosis were 68% and 86%, respectively, for the same thresholds ...

OBJECTIVES Antiretroviral interruption is associated with liver fibrosis progression in HIV/hepatitis C virus (HCV) coinfection. It is not known what level of HIV viraemia affects fibrosis progression. METHODS We evaluated 288 HIV/HCV-coinfected cohort participants with undetectable HIV RNA (<50 HIV-1 RNA copies/mL) on two consecutive visits while on combination antiretroviral therapy (cART) ...

BACKGROUND AND AIMS The aims of our study were to determine whether routine blood tests, the aspartate aminotransferase (AST) to Platelet Ratio Index (APRI) and Fibrosis 4 (Fib-4) scores, were associated with advanced fibrosis and to create a novel model in liver transplant recipients with chronic hepatitis C virus (HCV). METHODS We performed a cross sectional study of patients at The Univers...

Many studies used non-invasive methods to estimate the prevalence of significant fibrosis and its risk factors in patients with HIV infection. We evaluated the ability of APRI and FIB-4 score to differentiate between the different stages of fibrosis (no fibrosis/minimal fibrosis = F0-F1 and F2-F4 fibrosis moderate-severe/cirrhosis), taking as a reference, in the absence of liver biopsy, the hep...

Dear Editor, We read with great interest the recent article by Tapper et al. [1]. The authors aimed to determine the clinical predictors of advanced histology in the referral population. In multivariate logistic regression analyses, they have demonstrated that body mass index (BMI) 30 kg/m, female gender, and aspartate aminotransferase (AST) >40 IU/L were associated with a non-alcoholic fatty l...

BACKGROUND The prediction of fibrosis is an essential part of the assessment and management of patients with chronic liver disease. Non-invasive tests (NITs) have a number of advantages over the traditional standard of fibrosis assessment by liver biopsy, including safety, cost-effectiveness, and widespread accessibility. OBJECTIVES The aim of this study was to determine the accuracy of certa...

conclusions fib-4 confirmed the best value for diagnosis of significant fibrosis. apri had a sub-optimal diagnosis accuracy for significant fibrosis. lsm showed the most balance diagnosis value for cirrhosis with the highest sensitivity and moderate specificity. patients and methods a total of 544 patients with chb were assessed for fibrosis stage by four noninvasive tests containing liver stif...

Background: HIV-monoinfected patients may be at risk for significant liver fibrosis, but its prevalence and determinants in these patients are unknown. Since HIV-monoinfected patients do not routinely undergo liver biopsy, we evaluated the prevalence and risk factors of significant hepatic fibrosis in this group using the aspartate aminotransferase (AST)-to-platelet ratio index (APRI). Methods:...